The prevalence of class 1–3 variants was 9.42% in 1kGP (Supplementary Table S3) and 19.05% in KiCS (Supplementary Table S4), which was significantly lower than the 39.3% and 57.14% prevalence observed in the cancer-affected TP53-variant (Fisher exact test, 1kGP: P = 4.98 × 10−9; KiCS: P = 8.90 × 10−4) and TP53-wildtype (Fisher exact test, 1kGP: P = 1.29 × 10−5; KiCS: P = 1.56 × 10−3) groups (Supplementary Table S5), respectively (Fig. 2B). Here, TP53 is linked to cancer.